Emisphere Technologies, Inc.

Mannkind Corporation

Stauffer Chemical Company

Cytec Technology Corporation

Akzo America Inc.

Receptor Holdings, Inc.

American Cyanamid Company

Torrey Pines Institute for Molecular Studies

Ici Americas, Inc.

American Cyanamid

Technovax, Inc.

Mhr Institutional Partners Iia LP

Spoke Sciences, Inc.

Emishpere Technologies, Inc.

Andrea Leone-Bay

Donald J Sarubbi

Sam J Milstein

Koc-Kan Ho

Eric Yanjun Wang

Harry R Leipold

Nai Fang Wang

Peter E Timony

David Gschneidner

Destardi Moye-Sherman

Evgueni N Barantsevitch

Noemi B Santiago

Bryan R Wilson

Pingwah Tang

Duncan R Paton

Joseph J Guarneri

Doris C O'Toole

Marshall L Grant

John Smart

Grayson Walker Stowell

John J Freeman

Kelly Sullivan Kraft

Elliott Bay

Maria Aurora P Boyd

Gregory Wesner

Frenel DeMorin

Richard Allen Houghten

Paul S Waterman

Stanley S Kaminski

Joseph M Schmitt

Jun Liao

Puchun Liu

Jeffrey Bruce Press

Sun Y Huang

Susan Haas

Karine Fabio

Kieran Curley

Lynn Errigo

Chad C Smutney

Edward D Weil

Steven L Peake

John Tomko

Jeffery Bruce Press

Maria A P Boyd

David Gscheidner

Monica Leipold

Elizabeth Flanders

Donald J Sarrubi

George R Martin

Peter Richardson

Robert A Baughman

Jose M Galarza

John H Deatcher

George E Whitwell

Donald Costello

Stephen V Pusztay

Kirk A Simmons

Parshuram Rath

John J Weidner

Maria Isabel Gomez-Orellana

Jianfeng Song

Nai-Fang Wang

Hector Munoz

Lynn Shields

Laurel Glaser

Dawn M Carlson

Eric Wang

John E Smart

Monica Carozza

Doris O'TOOLE

The current disclosure provides use of N-acylated fatty amino acids to reduce absorption variability in cannabinoid-based compositions.

N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.

Diketopiperazine salts for drug delivery and related methods

Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

Fast-acting plant-based medicinal compounds and nutritional supplements

Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.

Heat-stable dry powder pharmaceutical compositions and methods

Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.

Methods and compositions for treating pain

Dry powder inhalable compositions and methods for using and making the compositions are disclosed for vaccinating a subject against disease. In particular, the compositions are inhalable dry powders useful for preventing and/or treating diseases caused by microorganisms, for example, microorganisms such as viral or bacterial pathogens, including, the influenza virus. In particular, the method comprises the administration of an inhalable composition comprising virus-like particles and/or specific protein/s or antigenic peptides, peptide fragments and/or derivatives thereof using a dry powder drug delivery system.

Inhalable vaccine compositions and methods

Growing community of inventors

Ridgefield, CT, United States of America

Andrea Leone-Bay